Rathbone Brothers plc Buys 2,358 Shares of Becton Dickinson and Co (BDX)

Rathbone Brothers plc increased its position in Becton Dickinson and Co (NYSE:BDX) by 3.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,769 shares of the medical instruments supplier’s stock after buying an additional 2,358 shares during the period. Rathbone Brothers plc’s holdings in Becton Dickinson and were worth $12,982,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Canada Pension Plan Investment Board increased its position in shares of Becton Dickinson and by 5.1% in the third quarter. Canada Pension Plan Investment Board now owns 37,389 shares of the medical instruments supplier’s stock worth $6,720,000 after buying an additional 1,816 shares during the period. BlackRock Inc. increased its position in shares of Becton Dickinson and by 4.0% in the third quarter. BlackRock Inc. now owns 669,945 shares of the medical instruments supplier’s stock worth $120,410,000 after buying an additional 25,651 shares during the period. WASHINGTON TRUST Co increased its position in shares of Becton Dickinson and by 148.2% in the third quarter. WASHINGTON TRUST Co now owns 93,600 shares of the medical instruments supplier’s stock worth $16,823,000 after buying an additional 55,896 shares during the period. Deroy & Devereaux Private Investment Counsel Inc. increased its position in shares of Becton Dickinson and by 0.6% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 90,825 shares of the medical instruments supplier’s stock worth $16,324,000 after buying an additional 558 shares during the period. Finally, BlackRock Investment Management LLC increased its position in shares of Becton Dickinson and by 30.4% in the third quarter. BlackRock Investment Management LLC now owns 1,449,399 shares of the medical instruments supplier’s stock worth $260,500,000 after buying an additional 337,535 shares during the period. 82.30% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Becton Dickinson and Co (NYSE:BDX) traded down 0.74% on Friday, hitting $184.68. 254,885 shares of the company traded hands. The firm has a market capitalization of $39.30 billion, a PE ratio of 30.74 and a beta of 1.00. Becton Dickinson and Co has a 1-year low of $157.60 and a 1-year high of $186.40. The firm’s 50 day moving average price is $183.77 and its 200 day moving average price is $175.25.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.11 by $0.22. The company earned $2.92 billion during the quarter, compared to analysts’ expectations of $2.86 billion. Becton Dickinson and had a return on equity of 25.25% and a net margin of 10.54%. The firm’s quarterly revenue was down 2.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.96 earnings per share. Equities research analysts predict that Becton Dickinson and Co will post $9.45 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 31st. Shareholders of record on Friday, March 10th were paid a dividend of $0.73 per share. The ex-dividend date was Wednesday, March 8th. This represents a $2.92 annualized dividend and a yield of 1.57%. Becton Dickinson and’s dividend payout ratio (DPR) is 48.42%.

ILLEGAL ACTIVITY WARNING: This story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/04/21/becton-dickinson-and-co-bdx-position-increased-by-rathbone-brothers-plc-updated.html.

Several equities research analysts have commented on the stock. Royal Bank of Canada reaffirmed a “hold” rating and set a $177.00 price objective on shares of Becton Dickinson and in a report on Friday, January 6th. Raymond James Financial, Inc. reaffirmed an “outperform” rating and set a $180.00 price objective (down from $200.00) on shares of Becton Dickinson and in a report on Thursday, January 5th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 price objective on the stock in a report on Tuesday, April 11th. JPMorgan Chase & Co. downgraded shares of Becton Dickinson and from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $190.00 to $175.00 in a report on Tuesday, January 3rd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $200.00 price objective on shares of Becton Dickinson and in a report on Wednesday, March 29th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Hold” and an average price target of $182.91.

In other Becton Dickinson and news, VP Jeffrey S. Sherman sold 31,464 shares of the firm’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $180.02, for a total transaction of $5,664,149.28. Following the completion of the sale, the vice president now owns 22,094 shares of the company’s stock, valued at $3,977,361.88. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.40% of the stock is owned by company insiders.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

5 Day Chart for NYSE:BDX

Receive News & Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply